Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Cermin Dunia Kedokteran Cermin Dunia Kedokteran
Achmad Faiz Sulaiman
Achmad Faiz Sulaiman Dokter Umum Klinik Utama Muhammadiyah Asy-Syifa Kudus, Indonesia
Health Professions Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Carvedilol untuk Tata Laksana Clinically Significant Portal Hypertension pada Sirosis Kompensata Achmad Faiz Sulaiman
Cermin Dunia Kedokteran Vol 50 No 3 (2023): Kardiologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v50i3.660

Abstract

Hipertensi portal merupakan konsekuensi klinis dari sirosis hati. Angka kematian karena hipertensi portal masih tinggi di Indonesia. Pada kondisi sirosis kompensata munculnya hipertensi portal yang signifikan secara klinis (clinically significant portal hypertension/CSPH) dapat memprediksi kejadian dekompensasi dan merupakan penanda prognosis penyakit yang lebih buruk. Diagnosis CSPH dapat dengan cara invasif ataupun non-invasif. Tata laksana CSPH pada kondisi sirosis kompensata diutamakan untuk mencegah timbulnya dekompensasi sirosis. Pemberian penghambat beta non-selektif (non-selective beta blocker/NSBB) pada kondisi sirosis kompensata efektif menurunkan hipertensi portal dan mampu mencegah dekompensasi. Portal hypertension is a major consequences of liver cirrhosis. Mortality rate from portal hypertension is quite high in Indonesia. In patients with liver cirrhosis, the development of clinically significant portal hypertension (CSPH) is predictive for decompensation and worse prognosis. Diagnosis of CSPH can be carried out by either invasive or non-invasive methods. The aim of CSPH management in compensated cirrhosis is to prevent the incidence of decompensation. Management of compensated cirrhosis with non-selective beta blocker (NSBB) has been shown to reduce portal hypertension and the incidence of first decompensation.
Carvedilol untuk Tata Laksana Clinically Significant Portal Hypertension pada Sirosis Kompensata Achmad Faiz Sulaiman
Cermin Dunia Kedokteran Vol 50 No 3 (2023): Kardiologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v50i3.660

Abstract

Hipertensi portal merupakan konsekuensi klinis dari sirosis hati. Angka kematian karena hipertensi portal masih tinggi di Indonesia. Pada kondisi sirosis kompensata munculnya hipertensi portal yang signifikan secara klinis (clinically significant portal hypertension/CSPH) dapat memprediksi kejadian dekompensasi dan merupakan penanda prognosis penyakit yang lebih buruk. Diagnosis CSPH dapat dengan cara invasif ataupun non-invasif. Tata laksana CSPH pada kondisi sirosis kompensata diutamakan untuk mencegah timbulnya dekompensasi sirosis. Pemberian penghambat beta non-selektif (non-selective beta blocker/NSBB) pada kondisi sirosis kompensata efektif menurunkan hipertensi portal dan mampu mencegah dekompensasi. Portal hypertension is a major consequences of liver cirrhosis. Mortality rate from portal hypertension is quite high in Indonesia. In patients with liver cirrhosis, the development of clinically significant portal hypertension (CSPH) is predictive for decompensation and worse prognosis. Diagnosis of CSPH can be carried out by either invasive or non-invasive methods. The aim of CSPH management in compensated cirrhosis is to prevent the incidence of decompensation. Management of compensated cirrhosis with non-selective beta blocker (NSBB) has been shown to reduce portal hypertension and the incidence of first decompensation.
Co-Authors